Naltrexone as a treatment of self‐injurious behavior — a case report

Griengl, H.; Sendera, A; Dantendorfer, K.

doi:10.1034/j.1600-0447.2001.00087.x

Cited by 38 publications

(20 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All together, these data do not seem to reveal cycle-related fluctuations of physiological aggressiveness, in accord with the report of Dougherthy et al (1998). This seems to contradict the data from the literature reporting relationships between sexual hormone concentrations, in particular FT and E, and aggressive behavior in women (Jnoff-Gormain et al, 1981;Simon and Whalen, 1986;Olweus et al, 1988;Gladue, 1991;Leibenluft et al, 1994;Gerra et al, 1996Gerra et al, , 1997Gerra et al, , 1998Finkelstein et al, 1997;Aromaki et al, 1999;Van Herringen et al, 2000;Grieng et al, 2001;Thiblin and Parlklo, 2002). However, these data refer to elevated or pathological or provoked aggressiveness related to hormonal secretions or administration, while we investigated the possible hormonal background of fluctuations of normal aggressiveness during the normal menstrual cycles in subjects in resting conditions.…”

Section: Discussioncontrasting

confidence: 77%

“…Also, it is well known that peripherally secreted hormones, including androgens, glucocorticoids and growth hormone and centrally secreted opioids influence the development and the degree of physiological and pathological aggressiveness in experimental animals (Grieng et al, 2001) and in humans (Olweus et al, 1988;Coccaro et al, 1997;Gerra et al, 1996Gerra et al, , 1997Gerra et al, , 1998Finkelstein et al, 1997;Archer et al, 1998;Aromaki et al, 1999;Van Herringen et al, 2000;Pope et al, 2000;Grieng et al, 2001;Thiblin and Parlklo, 2002;O'Connor et al, 2002;Eriksson et al, 2003;Rowe et al, 2004). Little is known about the influence that female sexual hormones exert on this behavioral parameter, even though in experimental animals of both sexes, especially in major primates, aggressive behavior has been linked to variations of prenatal and postnatal estrogen secretions (Simon and Whalen, 1986;Finkelstein et al, 1997;Girolami et al, 1997;Palanza et al, 1999;Toda et al, 2001).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hormonal background of physiological aggressiveness in psychologically healthy women

Brambilla

Speca

Pacchiarotti

et al. 2010

International Journal of Psychophysiology

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 77%

Section: Introductionmentioning

confidence: 99%

Hormonal background of physiological aggressiveness in psychologically healthy women

Brambilla

Speca

Pacchiarotti

et al. 2010

International Journal of Psychophysiology

View full text Add to dashboard Cite

“…Acupuncture therapy has been shown to increase short- and long-term μ-opioid receptor binding potential [99], and a pilot study of ear acupuncture successfully reduced acts of NSSI among a group of depressed adolescents [100]. Additionally, case studies [96,101,102,103] and a pilot study with 5 participants [104] describe the successful use of naltrexone (an opioid receptor antagonist) in the treatment of NSSI. Buprenorphine, a μ-opioid partial agonist and κ-opioid antagonist, has also shown promise in case studies in reducing severe NSSI [105].…”

Section: Response Modulation and Nssimentioning

confidence: 99%

Nonsuicidal Self-Injury: An Emotion Regulation Perspective

2014

View full text Add to dashboard Cite

Background: Nonsuicidal self-injury (NSSI) is widely thought to serve an emotion-regulatory function. Method: The focus of the present paper is to provide a conceptual framework for understanding how NSSI might modify a person's emotions. Results: Drawing upon the process model of emotion regulation, we argue that 5 families of emotion regulation strategies may be engaged by NSSI. Individuals may engage in NSSI as an alternative to more distressing situations. They also may use NSSI to modify their social environment. Individuals may shift their attention away from unpleasant emotions or thoughts via NSSI. NSSI may change cognitions about the self via self-punishment or transformation of the self from higher-order to lower-order awareness. NSSI may also bring about various physiological effects, such as changes in endogenous opioids or parasympathetic nervous system activation, as a way of modulating emotional responses. Conclusion: Simply labeling NSSI as ‘emotion regulatory' does not tell us precisely what is going on. This is because at any given moment, NSSI can serve to regulate emotions in many different ways. One key challenge is to clarify the precise functions NSSI may be serving for a given individual in a particular context.

show abstract

“…Naloxone used during acute states of aversive tension and dissociation in BPD demonstrated no significant benefit (Philipsen et al 2004b). Naltrexone has been used successfully in open-label trials to treat self-harm (Griengl et al 2001 ;McGee, 1997 ;Roth et al 1996) and dissociation (Bohus et al 1999). Therefore, evidence for treatment of BPD with medications acting upon opioid receptors remains inconsistent.…”

Section: Other Medicationsmentioning

confidence: 96%

Evidence-based pharmacotherapy for personality disorders

Ripoll

Triebwasser

Siever

2011

Int. J. Neuropsychopharm.

View full text Add to dashboard Cite

Patients with personality disorders are prescribed psychotropic medications with greater frequency than almost any other diagnostic group. Prescribing practices in these populations are often based on anecdotal evidence rather than rigorous data. Although evidence-based psychotherapy remains an integral part of treatment, Axis II psychopathology is increasingly conceptualized according to neurobiological substrates that correspond to specific psychopharmacological strategies. We summarize the best available evidence regarding medication treatment of personality disordered patients and provide optimal strategies for evidence-based practice. Most available evidence is concentrated around borderline and schizotypal personality disorders, with some additional evidence concerning the treatment of avoidant and antisocial personality disorders. Although maladaptive personality symptoms respond to antidepressants, antipsychotics, mood stabilizers, and other medications, evidence-based pharmacotherapy is most useful in treating circumscribed symptom domains and induces only partial improvement. Most available evidence supports use of medication in reducing impulsivity and aggression, characteristic of borderline and antisocial psychopathology. Efforts have also begun to reduce psychotic-like symptoms and improve cognitive deficits characteristic of schizotypy. Indirect evidence is also provided for psychopharmacological reduction of social anxiety central to avoidant personality disorder. Evidence-based practice requires attention to domains of expected clinical improvement associated with a medication, relative to the potential risks. The development of future rational pharmacotherapy will require increased understanding of the neurobiological underpinnings of personality disorders and their component dimensions. Increasing efforts to translate personality theory and social cognitive neuroscience into increasingly specific neurobiological substrates may provide more effective targets for pharmacotherapy.

show abstract

Naltrexone as a treatment of self‐injurious behavior — a case report

Abstract: Naltrexone could be effective in reducing SIB in patients with psychiatric disorders by blocking the positive reinforcement of SIB, which is released by the release of endogenous opoides. Placebo-controlled studies of the efficacy of naltrexone in treating SIB should be undertaken.

Cited by 38 publications

References 8 publications

Hormonal background of physiological aggressiveness in psychologically healthy women

Hormonal background of physiological aggressiveness in psychologically healthy women

Nonsuicidal Self-Injury: An Emotion Regulation Perspective

Evidence-based pharmacotherapy for personality disorders

Contact Info

Product

Resources

About